135 related articles for article (PubMed ID: 3289292)
1. Insulin/C-peptide response to intravenous glucagon. A dose-response study in normal and non-insulin-dependent diabetic subjects.
Snorgaard O; Hasselstrøm K; Lumholtz IB; Thorsteinsson B; Siersbaek-Nielsen K
Acta Endocrinol (Copenh); 1988 Jan; 117(1):109-15. PubMed ID: 3289292
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus.
Park SW; Ihm SH; Yoo HJ; Park JY; Lee KU
Diabetes Res Clin Pract; 1997 Sep; 37(3):165-71. PubMed ID: 9306037
[TBL] [Abstract][Full Text] [Related]
3. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
Kruszynska YT; Goulas S; Wollen N; McIntyre N
J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541
[TBL] [Abstract][Full Text] [Related]
4. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
5. Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships.
Ahrén B; Nobin A; Scherstén B
Acta Med Scand; 1987; 221(2):185-90. PubMed ID: 3296670
[TBL] [Abstract][Full Text] [Related]
6. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes.
Gredal C; Rosenfalck AM; Dejgaard A; Hilsted J
Scand J Clin Lab Invest; 2007; 67(3):327-36. PubMed ID: 17454847
[TBL] [Abstract][Full Text] [Related]
7. The beta-cell response to glucagon and mixed meal stimulation in non-insulin dependent diabetes.
Gjessing HJ; Damsgaard EM; Matzen LE; Faber OK; Frøland A
Scand J Clin Lab Invest; 1988 Dec; 48(8):771-7. PubMed ID: 3070718
[TBL] [Abstract][Full Text] [Related]
8. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
9. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.
Gjessing HJ; Damsgaard EM; Matzen LE; Frøland A; Faber OK
Diabetes Care; 1987; 10(5):558-62. PubMed ID: 3315512
[TBL] [Abstract][Full Text] [Related]
11. Islet hormonal regulation of glucose turnover during exercise in type 1 diabetes.
Shilo S; Sotsky M; Shamoon H
J Clin Endocrinol Metab; 1990 Jan; 70(1):162-72. PubMed ID: 1967178
[TBL] [Abstract][Full Text] [Related]
12. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
Glaser B; Leibovich G; Nesher R; Hartling S; Binder C; Cerasi E
Acta Endocrinol (Copenh); 1988 Jul; 118(3):365-73. PubMed ID: 3293339
[TBL] [Abstract][Full Text] [Related]
13. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-glucose (GG) test for the estimation of the insulin reserve in diabetes.
Miki H; Matsuyama T; Fujii S; Komatsu R; Nishioeda Y; Omae T
Diabetes Res Clin Pract; 1992 Nov; 18(2):99-105. PubMed ID: 1478158
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.
Wolffenbuttel BH; Menheere PP; Nijst L; Rondas-Colbers GJ; Sels JP; Nieuwenhuijzen Kruseman AC
Neth J Med; 1992 Jun; 40(5-6):277-82. PubMed ID: 1436266
[TBL] [Abstract][Full Text] [Related]
16. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
[TBL] [Abstract][Full Text] [Related]
17. Repeatability of C-peptide response in glucagon stimulation test.
Sarlund H; Siitonen O; Laakso M; Pyörälä K
Acta Endocrinol (Copenh); 1987 Apr; 114(4):515-8. PubMed ID: 3577583
[TBL] [Abstract][Full Text] [Related]
18. Plasma C-peptide and insulin responses to intravenous glucagon stimulation in idiopathic haemochromatosis.
Rumbak MJ; Joffe BI; Seftel HC; Kalk WJ; Bezwoda WR; Bothwell TH
S Afr Med J; 1987 Mar; 71(6):351-3. PubMed ID: 3551126
[TBL] [Abstract][Full Text] [Related]
19. Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus.
Dimitriadis GD; Pehling GB; Gerich JE
Diabetes; 1985 Jun; 34(6):541-7. PubMed ID: 3891467
[TBL] [Abstract][Full Text] [Related]
20. [Clinical usefulness of the glucagon test in the study of pancreatic islet cell function].
Llorente I; Goñi MJ; Forga L; Monreal M; Lizcano F; Moncada E
Rev Med Univ Navarra; 1992; 37(1):25-9. PubMed ID: 1626165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
